Nutra Pharma Widens H1 2025 Loss to $1.04M Despite 77% Revenue Gain
Nutra Pharma Corp., a pharmaceutical company, reported a net loss of $1.04 million for the six months ending June 30, 2025, compared to a loss of $794,073 in the same period last year. Revenue climbed 77% to $158,506.
Nutra Pharma Corp., a pharmaceutical company, reported a net loss of $1.04 million for the six months ending June 30, 2025, compared to a loss of $794,073 in the same period last year. Revenue climbed 77% to $158,506 from $89,442, but surging operating expenses more than offset the sales gain. Read more earnings reports.
Operating expenses jumped 30% to $784,307 in the first half of 2025, up from $604,844 a year earlier. The company posted an operating loss of $640,348 for the period, widening from a loss of $514,802 in the prior year. Gross profit rose to $143,959 from $90,042, reflecting improved margins as cost of goods sold increased at a slower pace than revenue.
For the three months ending June 30, 2025, the company reported net income of $369,577, a sharp reversal from a loss of $367,139 in the second quarter of 2024. Revenue for the quarter totaled $84,532, up 63% from $51,710 a year earlier. The quarterly turnaround contrasts with the accumulated first-half loss, driven by non-operating items that reduced the bottom line in earlier months.
Cash from operations was negative $693,376 for the six months, deteriorating from negative $264,822 in the prior-year period. The company raised $787,050 through financing activities, compared to $265,822 a year earlier, while cash used in investing activities totaled $51,052.
Balance Sheet
Total assets increased to $859,068 as of June 30, 2025, from $599,495 at year-end 2024. Current assets rose to $665,128 from $374,837, while property, plant and equipment jumped to $31,146 from $10,402. Inventory declined slightly to $15,658 from $17,696.
Total liabilities climbed to $16.69 million from $15.41 million at the end of 2024. Current liabilities stood at $16.55 million, up from $15.27 million. Accounts payable edged down to $793,637 from $802,314. Long-term debt decreased to $138,447 from $140,217.
Stockholders' equity remained deeply negative at $15.83 million as of June 30, 2025, compared to negative $14.81 million at year-end 2024. Retained deficit widened to $77.27 million from $76.23 million. The company had 7.1 billion common shares outstanding at the end of the period.
Key Financials
| Metric | H1 2025 | H1 2024 | Change |
|---|---|---|---|
| Revenue | $158,506 | $89,442 | +77% |
| Cost of Goods Sold | $83,578 | $41,108 | +103% |
| Gross Profit | $143,959 | $90,042 | +60% |
| Operating Expenses | $784,307 | $604,844 | +30% |
| Operating Loss | ($640,348) | ($514,802) | -24% |
| Net Loss | ($1,035,346) | ($794,073) | -30% |
| Cash from Operations | ($693,376) | ($264,822) | -162% |
Earnings per share were reported as $0.00 on both a basic and diluted basis for the six months ending June 30, 2025, compared to negative $0.00 in the prior year, reflecting the minimal impact per share given the large share count.